Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists June 26-29, in Seattle, Washington.

8 Jul 2013

Mothers commonly talk to children about genetic test even it they test positive for gene mutation

Mothers commonly talk to their children about genetic test results even if they test positive for a BRCA1 or BRCA2 gene mutation, which sharply increases a woman's risk of developing breast and ovarian cancer.

3 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Chlamydia trachomatis is a human pathogen that is the leading cause of bacterial sexually transmitted disease worldwide with more than 90 million new cases of genital infections occurring each year. About 70 percent of women infected with Chlamydia remain asymptomatic and these bacteria can establish chronic infections for months, or even years. Even when it causes no symptoms, Chlamydia can damage a woman's reproductive organs. In addition, standard antibacterial drugs are proving increasingly ineffective in complete eradication, as Chlamydia goes in to persistent mode, leading to asymptomatic chronic infection.

21 Jun 2013

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.

19 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Pathway Genomics to provide genetic testing for BRCA gene linked to breast, ovarian cancers

Pathway Genomics led the evening news Friday with an announcement that it could begin offering affordable access to genetic testing for the BRCA gene linked to breast and ovarian cancers in the wake of a Supreme Court ruling that eliminated another company's monopoly on the test.

15 Jun 2013

Supreme Court invalidates patents held by Myriad Genetics

The College of American Pathologists applauds today's unanimous Supreme Court decision invalidating the patents held by Myriad Genetics on the BRCA1 and BRCA2 genes. It is a victory for patients and for science.

14 Jun 2013

Ambry Genetics introduces BRCA1 and BRCA2 analysis

Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility genes using next-generation sequencing technology.

14 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Combination of cell-killing radioactive particle and antibody is safe for treating cancers

An experimental treatment that combines a cell-killing radioactive particle with an antibody that homes in on cancer cells is safe in the treatment of cancers spreading through patients' abdomens, according to data from a first-in-human study presented today at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver.

11 Jun 2013

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

MRI scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance.

10 Jun 2013

Genetic testing for cancer-causing mutations in affected families is very low, study finds

A new study of the use of genetic testing for cancer-causing mutations in affected families in France has found that its take-up is very low.

10 Jun 2013

Thomson Reuters announces this year's Hottest Researchers

The Intellectual Property & Science business of Thomson Reuters today announced this year's Hottest Researchers, a ranking of the most influential scientific researchers and research papers on ScienceWatch, the open web resource for science metrics and analysis.

5 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Scientists pinpoint genetic traits of cells that give rise to gliomas

A multi-institutional team of researchers have pinpointed the genetic traits of the cells that give rise to gliomas - the most common form of malignant brain cancer. The findings, which appear in the journal Cell Reports, provide scientists with rich new potential set of targets to treat the disease.

4 Jun 2013

African-American women carry inherited genetic mutations that increase their risk for breast cancer

A high percentage of African-American women with breast cancer who were evaluated at a university cancer-risk clinic were found to carry inherited genetic mutations that increase their risk for breast cancer.

4 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Mothers commonly talk to children about genetic test even it they test positive for gene mutation

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Pathway Genomics to provide genetic testing for BRCA gene linked to breast, ovarian cancers

Supreme Court invalidates patents held by Myriad Genetics

Ambry Genetics introduces BRCA1 and BRCA2 analysis

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Combination of cell-killing radioactive particle and antibody is safe for treating cancers

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

Genetic testing for cancer-causing mutations in affected families is very low, study finds

Thomson Reuters announces this year's Hottest Researchers

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Scientists pinpoint genetic traits of cells that give rise to gliomas

African-American women carry inherited genetic mutations that increase their risk for breast cancer

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in